No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DAWN240517P15000
- 0.20
- -0.05-20.00%
15min DelayClose May 9 15:55 ET
0.30High0.20Low
0.30Open0.25Pre Close2 Volume547 Open Interest15.00Strike Price50.00Turnover74.13%IV-9.65%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type-0.1921Delta0.1527Gamma81.90Leverage Ratio-0.0307Theta-0.0007Rho-15.73Eff Leverage0.0066Vega
Intraday
- 5D
- 1D
News
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Express News | Day One Biopharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $40 From $50
Express News | Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Day One Biopharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 98.19% Needham → $33 Reiterates Buy → Buy 04/25/2024 98.19% Needham → $33 Reiterates Buy → Buy
Express News | Day One Biopharmaceuticals Inc Q1 Shr View $-0.66 -- Lseg Ibes Data
Comments
📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
11
4
$Day One Biopharmaceuticals(DAWN.US$ Its actually moving 2 days in a row after FDA approval and voucher from 5 days ago! Hehehe
1
$Day One Biopharmaceuticals (DAWN.US)$ live conference this morning. they got a special exemption that can ge sold for 100 to 150million or transfered to another biotech. it's an expedited voucher for doing such a good job with the PDUFA. sounds make up, but a real thing.
they have 319milliom cash ok hand ans sales force ready to go. I'm listening in! 😏
they have 319milliom cash ok hand ans sales force ready to go. I'm listening in! 😏
3
1
Nice push up today. Here are the levels to keep an eye on. Watch the GAP at 17.85
Larger Image: tradingview.com...
$Day One Biopharmaceuticals(DAWN.US$
Larger Image: tradingview.com...
$Day One Biopharmaceuticals(DAWN.US$
$Day One Biopharmaceuticals(DAWN.US$ bleeding more and more every quarter
must be why it didn't bounce higher off FDA news
must be why it didn't bounce higher off FDA news
Read more
J L 7 2 : 为啥股票还是软趴趴 没力向上呢
73125363 J L 7 2: 在蓄力吧
Master Corgi : Your pic gained you many followers
Vijay Raja : BEQVEZ has the same problem that Roctavian has. Payers have not been sorted . Very slow uptake.